Browse the complete record of transactions filed by Sébastien Peltier, CEO, Co-founder and Chairman of the Management Board at Valbiotis. Director active across 1 companies, notably VALBIOTIS. Cumulatively, 2 filings have been logged. Total volume traded: €142k. The latest transaction was disclosed on 30 June 2025 — Acquisition. Regulator: AMF. The full history is accessible without signup.
2 of 2 declarations
Sébastien Peltier is the CEO, co-founder and Chairman of the Management Board of Valbiotis, a French health company focused on science-driven innovation and patented plant-based active ingredients. His background is rooted in nutrition and cardio-metabolic health. He completed a doctoral thesis in nutrition at Université Joseph Fourier in Grenoble, within the INSERM laboratory of Fundamental and Applied Bioenergetics, under Professor Xavier Leverve. This academic foundation shaped his profile as a scientist-entrepreneur and a leader with a strong focus on prevention, translational research and value creation through innovation. Before co-founding Valbiotis, he worked for a spin-off of the Free University of Brussels in Belgium on a drug candidate in the field of enteral and parenteral nutrition. In 2007, he joined the Lescuyer Laboratory, where he was quickly entrusted with the Research and Development function. There, he oversaw a scientific and regulatory process that helped deliver one of the very few health claims ever to receive a positive opinion from EFSA for reducing a cardiovascular risk factor. This milestone highlights his ability to bridge scientific rigor, regulatory strategy and commercial potential—an especially valuable combination in the nutraceutical and preventive health sectors. At Valbiotis, Sébastien Peltier has been a central figure in the company’s main development phases: its creation in La Rochelle in 2015, the discovery of the TOTUM•63 active ingredient in 2017, the listing on Euronext Growth in 2020, and the subsequent expansion of the pipeline with additional active compounds. Valbiotis positions itself around a unique scientific model based on patented botanical blends designed to address major metabolic disorders. Under his leadership, the company has strengthened its governance, investor relations and ESG commitment, while building its credibility as a long-term health innovation platform. Overall, Sébastien Peltier stands out as a biotech executive combining scientific depth, entrepreneurial discipline and strategic execution.